Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge.

[1]  R. Boshuizen,et al.  Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[2]  C. Stokes,et al.  Mucosal infection and vaccination against feline immunodeficiency virus. , 1999, Journal of biotechnology.

[3]  L. Bergmeier,et al.  The effect of route of immunization on mucosal immunity and protection. , 1999, The Journal of infectious diseases.

[4]  T. Hirst,et al.  Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. , 1999, Immunology today.

[5]  J. Neil,et al.  Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes. , 1999, Immunology.

[6]  J. Blanchard,et al.  Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. , 1999, Journal of immunology.

[7]  J. Mcghee,et al.  Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. , 1998, Journal of immunology.

[8]  T. Gruffydd-Jones,et al.  Determination of salivary and serum immunoglobulin concentrations in the cat. , 1998, Veterinary immunology and immunopathology.

[9]  T. Lehner,et al.  beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Onions,et al.  DNA Vaccination Affords Significant Protection against Feline Immunodeficiency Virus Infection without Inducing Detectable Antiviral Antibodies , 1998, Journal of Virology.

[11]  K. Rosenthal,et al.  Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. , 1998, The Journal of infectious diseases.

[12]  J. Berzofsky,et al.  Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Soos,et al.  Perspectives on FIV vaccine development. , 1997, Vaccine.

[14]  H. Staats,et al.  Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. , 1997, AIDS research and human retroviruses.

[15]  J. N. Flynn,et al.  FIV infection of the domestic cat: an animal model for AIDS. , 1997, Immunology today.

[16]  E. Hoover,et al.  Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. , 1997, AIDS research and human retroviruses.

[17]  D. Lu,et al.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239 , 1997, Journal of virology.

[18]  J. Cox,et al.  Adjuvants--a classification and review of their modes of action. , 1997, Vaccine.

[19]  J. N. Flynn,et al.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection , 1996, Journal of virology.

[20]  C. Stokes,et al.  Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. , 1996, Vaccine.

[21]  C. Stokes,et al.  Vaginal and rectal infection of cats with feline immunodeficiency virus. , 1996, Veterinary microbiology.

[22]  S. Kent,et al.  Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination , 1996, Journal of virology.

[23]  Yufei Wang,et al.  Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques , 1996, Nature Medicine.

[24]  M. Pistello,et al.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies , 1996, Journal of virology.

[25]  M. Marinaro,et al.  Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. , 1995, Journal of immunology.

[26]  J. Neil,et al.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. , 1995, Immunology.

[27]  J. Neil,et al.  Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines , 1995, Journal of virology.

[28]  M Pistello,et al.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen , 1995, Clinical microbiology reviews.

[29]  M. Clerici,et al.  The Th1-Th2 hypothesis of HIV infection: new insights. , 1994, Immunology today.

[30]  M. Pistello,et al.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity , 1994, Journal of virology.

[31]  J. Neil,et al.  Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide , 1994, Journal of virology.

[32]  T. Lehner,et al.  T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Bendinelli,et al.  Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope , 1993, Journal of virology.

[34]  M. Gardner,et al.  Experimental vaccine protection against feline immunodeficiency virus. , 1991, AIDS research and human retroviruses.

[35]  D. Lloyd,et al.  HBTU activation for automated Fmoc solid-phase peptide synthesis. , 1991, Peptide research.

[36]  N. Pedersen,et al.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. , 1987, Science.